Zevra Therapeutics (ZVRA) Net Margin (2019 - 2026)
Zevra Therapeutics (ZVRA) reported Net Margin of 104.67% for Q1 2026, up 11986.0% on a YoY basis from N/an in Q1 2025, and up 194.0% quarter-over-quarter from 35.6% in Q4 2025.
Zevra Therapeutics (ZVRA) Net Margin (2019 - 2026) Analysis & Trends
Zevra Therapeutics has reported Net Margin for 8 years, with the latest figure at 104.67% in Q1 2026.
- For the quarter ending Q1 2026, Net Margin rose 11986.0% year-over-year to 104.67%; the trailing twelve-month figure through Mar 2026 stood at 101.56% (up 32864.0% YoY), and the FY2025 full-year result was 78.17%, up 52502.0% from the prior year.
- Net Margin for Q1 2026 stood at 104.67%, up from 35.6% in the prior quarter.
- The five-year high for Net Margin was 288.66% in Q2 2025, with the low at 50087.5% in Q2 2022.
- Historically, Net Margin has averaged 3142.11% across 5 years, with a median of 230.2% in 2022.
- Annual changes were most pronounced in 2022 — Net Margin sank 4999827 bps — and 2023, when it jumped 5005712 bps.
- Zevra Therapeutics' Net Margin stood at 411.35% in 2022, then soared by 63 bps to 153.96% in 2023, then plunged by 93 bps to 297.53% in 2024, then surged by 112 bps to 35.6% in 2025, then surged by 194 bps to 104.67% in 2026.
- The last three Net Margin figures came in at 104.67% (Q1 2026), 35.6% (Q4 2025), and 2.09% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 0.82% |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 34.53% |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Zevra Therapeutics | 704.96 Mn | 504.34 Mn | 34.30 Mn | 104.67% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 104.67% |
| Dec 31, 2025 | 35.60% |
| Sep 30, 2025 | -2.09% |
| Jun 30, 2025 | 288.66% |
| Mar 31, 2025 | -15.19% |
| Dec 31, 2024 | -297.53% |
| Sep 30, 2024 | -899.19% |
| Jun 30, 2024 | -452.84% |
| Mar 31, 2024 | -488.88% |
| Dec 31, 2023 | -153.96% |
| Sep 30, 2023 | -358.10% |
| Jun 30, 2023 | -30.38% |
| Mar 31, 2023 | -370.50% |
| Dec 31, 2022 | -411.35% |
| Sep 30, 2022 | -230.20% |
| Jun 30, 2022 | -50,087.50% |
| Mar 31, 2022 | -47.01% |
| Dec 31, 2021 | -104.69% |
| Sep 30, 2021 | -89.52% |
| Jun 30, 2021 | -89.23% |